Fig. 6From: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis6A, multivariable analysis for PFS; 6B, multivariable analysis for OS.Back to article page